Immunomodulatory Activities of the Benzoxathiole Derivative BOT-4-One Ameliorate Pathogenic Skin Inflammation in Mice  by Lee, Hyun Gyu et al.
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Ameliorate Pathogenic Skin Inflammation
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Hyun Gyu Lee1, Nam-chul Cho2, Ae Jin Jeong3, Yu-Chen Li4, Sung-Ja Rhie5, Jung Sook Choi6,
Kwang-Ho Lee7, Youngsoo Kim8, Yong-Nyun Kim9, Myoung-Hwan Kim10,11,12,13, Ae Nim Pae2,
Sang-Kyu Ye3,11,12,14 and Byung-Hak Kim3,14T-cell-mediated immune responses play an important role in body protection. However, aberrantly activated
immune responses are responsible for inflammatory and autoimmune diseases. The regulation of pathologic
immune responses may be a potential therapeutic strategy for the treatment of these diseases. Despite that
multiple pharmacologic properties of benzoxathiole derivatives have been defined, the molecular mechanisms
underlying these properties remain to be clarified. Here, we demonstrated the benzoxathiole derivative
2-cyclohexylimino-6-methyl-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one (BOT-4-one) regulated immune re-
sponses and ameliorated experimentally induced inflammatory skin diseases both in vitro and in vivo. BOT-4-
one inhibited the differentiation of CD4þ T-cell subsets by regulating the expression and production of T-cell
lineage-specific master transcription factors and cytokines and activating the signal transducer and activator of
transcription proteins. In addition, BOT-4-one inhibited TCR-mediated Akt and NF-kB signaling. Topical
application of BOT-4-one ameliorated experimentally induced inflammatory skin diseases in mice models such
as 2,4,6-trinitrochlorobenzene-induced contact and atopic dermatitis and IL-23-induced psoriasis-like skin
inflammation. Our study demonstrated that BOT-4-one ameliorates inflammatory skin diseases by suppressing
the pathogenic CD4þ T cell differentiation and overall immune responses.
Journal of Investigative Dermatology (2016) 136, 107-116; doi:10.1038/JID.2015.384INTRODUCTION
Many types of immune cells, including macrophages, natural
killer cells, and antigen-specific T lymphocytes, are activated
during cell-mediated immune responses to protect the body
against pathogens and immune reactions. Helper CD4þ T
cells are important components of immune cells to regulate
the immune response to intracellular and extracellular path-
ogens by activation of macrophages and cytotoxic T cells,
releasing T-cell cytokines, and B-cell antibody class switching
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producing anti-inflammatory cytokines such as IL-10 and
transforming growth factor-b (Sakaguchi et al., 2009). How-
ever, efficient pathogen-specific CD4þ T cells are differenti-
ated into effector subsets of CD4þ T cells, known as T helper
(Th) cell subsets, during the progression of chronic diseases.
In this circumstance, CD4þ T cells lose their immunosup-
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108Furthermore, these cell subsets exasperate the progression of
diseases by generating lineage-specific signature cytokines
(Zhu and Paul, 2008; Zhu et al., 2010).
The differentiation of naı¨ve CD4þ T cells into distinct T-cell
subsets depends on appropriate environmental conditions
and is regulated by complex networks of cytokines, master
transcription factors, and signal transducer and activator of
transcription (STAT) proteins, followed by TCR activation
triggered by antigen-presenting cells (Yamane and Paul,
2012; Zhu and Paul, 2008; Zhu et al., 2010). The activated
STAT proteins induce the expression of lineage-specific
master transcription factors, including T-box expressed in T
cells (T-bet), GATA binding protein 3 (GATA-3), retinoic acid
receptor-related orphan receptor gamma t (RORgt), and
forkhead box P3 (FoxP3) during T-cell differentiation. The T-
cell subsets produce lineage-specific effector cytokines,
leading to numerous immune diseases including allergy,
asthma, and autoimmune diseases (Del Prete, 1992; Guo
et al., 2009; Harrington et al., 2005), indicating that the
regulation of the differentiation of naı¨ve CD4þ T cells into
pathogenic effector T-cell subsets may be a potential thera-
peutic strategy for the treatment of these diseases.
Benzoxathiole derivatives have been used in the treatment
of acne and are reported to have pharmacologic properties
such as antipsoriatic, antibacterial, antimicrobial, anti-
mycotic, and cytostatic activities (Goeth and Wildfeuer,
1969; Lius and Sennerfeldt, 1979; Wildfeuer, 1970). How-
ever, the molecular basis of these pharmacologic activities
remains to be defined. Here, we demonstrated that
the benzoxathiole derivative BOT-4-one exhibits T-cell-
mediated immunomodulatory activities. BOT-4-one regu-
lated CD4þ T-cell differentiation and ameliorated 2,4,
6-trinitrochlorobenzene (TNCB)- or IL-23-induced inflam-
matory skin diseases in mice. Our results suggest that BOT-4-
one is a potential small molecule for amelioration of the
inflammatory skin diseases caused by pathogenic effector
T-cell subset-mediated immune responses through regulation
of the CD4þ T-cell differentiation and the overall immune
response.
RESULTS
BOT-4-one regulates CD4D T-cell differentiation
The benzoxathiole derivative BOT-4-one exhibits weak to no
cytotoxic activity in cultured mouse CD4þ T cells and
RAW264.7 cells in vitro at concentrations of up to 40 mM for
24 hours (see Supplementary Figure S1, online). BOT-4-one
was treated up to 30 mM in the in vitro experiments to
minimize the possibility of cytotoxic effects. To examine
whether BOT-4-one could regulate immune responses,
particularly with regard to CD4þ T cell differentiation, we
determined the mRNA levels of master transcription factors
associated with T-cell subsets in mouse CD4þ T cells. The
mRNA levels of T-bet, GATA-3, and RORgt, which are the
master transcription factors for Th1, Th2, and Th17 cells,
respectively, were suppressed by BOT-4-one. In contrast,
treatment with BOT-4-one upregulated mRNA levels of the
Treg-cell master transcription factor FoxP3 (Figure 1a). We
further examined the effects of BOT-4-one on the expression
of T-cell subset-specific signature cytokines. The mRNA
levels of Th1 lineage-specific cytokine IFN-g, Th2 lineage-Journal of Investigative Dermatology (2016), Volume 136specific cytokine IL-4, and Th17 lineage-specific cytokines
IL-17A and IL-22 were decreased by BOT-4-one (Figure 1b).
In parallel with these results, BOT-4-one suppressed the
production of IFN-g, IL-4, and IL-17A (Figure 1c). However,
the mRNA levels and production of anti-inflammatory cyto-
kine IL-10 were increased by BOT-4-one in the Th2 and Treg
cell subsets (Figure 1b and c). To delineate whether the
regulation of CD4þ T-cell differentiation is involved in cell
proliferation, we determined proliferation of the activated
T cells using FACS (BD LSRII, BD Biosciences, San Jose, CA)
analysis followed by staining with carboxyfluorescein
succinimidyl ester; the carboxyfluorescein succinimidyl
ester-labeled cell population was reduced by BOT-4-one
treatment compared with the vehicle-treated group (see
Supplementary Figure S2, online). These results suggested
that BOT-4-one might have immunomodulatory effects by
regulating CD4þ T cell differentiation.
BOT-4-one inhibits activation of STAT proteins
Cytokine-mediated activation of STAT proteins plays an
essential role in CD4þ T-cell differentiation and regulation of
immune responses (O’Shea et al., 2011). To address the effect
of BOT-4-one on STAT signaling, mouse CD4þ T cells and
RAW264.7 cells were incubated with various cytokines with
or without BOT-4-one. STAT proteins, including STAT1, 3, 4, 5,
and 6, were markedly activated by stimulation with T-cell
lineage-specific cytokines such as IFN-g, IL-2, IL-4, IL-6, and
IL-12 that showed phosphorylation of specific tyrosine resi-
dues. BOT-4-one potently inhibited cytokine-induced tyrosine
phosphorylation of STAT proteins (Figure 2). The inhibitory
effects of BOT-4-one were confirmed and compared with
those of AG-490, a pan-JAK inhibitor. These inhibitory activ-
ities of BOT-4-one indicated that this compound could
potently suppress STAT-dependent CD4þ T-cell differentiation.
BOT-4-one inhibits TCR-mediated Akt signaling
Numerous signaling cascades play a role in TCR-mediated
immune responses from T-cell microenvironments. Among
these signaling cascades, Src family tyrosine kinases are
important TCR proximal signaling components and essential
for the survival of naı¨ve T cells (Salmond et al., 2009; Seddon
and Zamoyska, 2002). The Src family kinases, including Lck,
Lyn, and Src, were activated in the presence of both anti-CD3
and anti-CD28 antibodies in mouse T cells. Interestingly,
BOT-4-one exhibited weak to no inhibitory activity in the
activation of these Src family kinases, whereas the inhibitor of
Src family kinases PP2 effectively inhibited activation of these
proteins (Figure 3a and see Supplementary Figure S3, online).
We next examined whether BOT-4-one affected TCR distal
signaling cascades. Among the cascades, phosphatidylinosi-
tol 3-kinase/Akt signaling is also controlled by TCR-mediated
signaling (Brownlie and Zamoyska, 2013; Huse, 2009). The
Akt protein was markedly activated by stimulation with both
anti-CD3 and anti-CD28 antibodies or lipopolysaccharide
(LPS) in mouse T cells and RAW264.7 cells, whereas this
activation was effectively inhibited by BOT-4-one and the
phosphatidylinositol 3-kinase inhibitor LY294002 (Figure 3b).
BOT-4-one inhibits NF-kB signaling
NF-kB signaling, which is activated by inflammatory cyto-
kines and bacterial components such as LPS and zymosan by
Figure 1. BOT-4-one regulates CD4D T cell differentiation. (a and b) Naı¨ve CD4þ T cells were differentiated under appropriate differentiation conditions for 5
days in the presence or absence of BOT-4-one (30 mM), as described in Materials and Methods. Total RNA was isolated and quantitative real-time PCR
performed to analyze the levels of T-cell lineage-specific master transcription factors (a) and cytokines (b). (c) Cytokine amounts were measured by ELISA using
the cultured supernatants. **P < 0.005 versus undifferentiated group (n ¼ 3). BOT-4, BOT-4-one.
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the immune response (Brownlie and Zamoyska, 2013; Huse,
2009). This signaling is activated by stimulation with both
anti-CD3 and anti-CD28 antibodies or either LPS or zymosan
in CD4þ T cells and RAW264.7 cells, which was observed
based on the levels of phosphorylation of IkBa, NF-kB p65,
and IkB kinase alpha/beta (IKKa/b) proteins, as well as
degradation of IkBa protein. BOT-4-one effectively inhibited
the phosphorylation and degradation of NF-kB signaling
components (Figure 3c). We next examined NF-kB reporter
activity by measuring NF-kB-dependent secretory alkaline
phosphatase (SEAP) expression in RAW264.7/NF-kB-SEAP-
NPT cells. SEAP expression increased after stimulation with
either LPS or zymosan, whereas BOT-4-one effectively
inhibited this expression (see Supplementary Figure S4a,
online). Similar results were observed with NF-kB-dependent
luciferase activity in RAW264.7 cells. In addition, in the
absence of BOT-4-one, LPS-stimulated NF-kB reporter ac-
tivity was not restored in the dominant-negative mutant IkBa,
which was substituted serine-to-alanine at amino acids 32
and 36 (Supplementary Figure S4b). These results indicated
that BOT-4-one is a potent inhibitor of NF-kB signaling and
may target upstream of the NF-kB/IkBa complex.
BOT-4-one targets cysteine-179 of IKKb
The NF-kB pathway is comprises sequential signaling cas-
cades. Among the cascades, the IKK complex composed of
IKKa, IKKb, and NF-kB essential modulator is an upstreamsignal of the NF-kB/IkBa complex and directly phosphorylates
IkBa protein (Israe¨l, 2010). To identify the primary targets of
BOT-4-one, we measured SEAP expression followed by trans-
fection with the expression vectors encoding TRAF-2, MyD88,
MEKK-1, NIK-1, IKKb, NF-kB p50, or NF-kB p65, which are
components of NF-kB signaling, in RAW264.7/NF-kB-SEAP-
NPT cells. SEAP expression increased after transfection
with the expression vectors, which was similar with LPS stim-
ulation. BOT-4-one effectively inhibited this expression eli-
cited by upstream components of the NF-kB/IkB complex,
including TRAF-2, MyD88, MEKK-1, NIK-1, and IKKb, similar
to that of LPS stimulation. In contrast, this expression was not
affected by overexpression of NF-kB p50 and p65 subunits in
the presence of BOT-4-one (Figure 4a), indicating that the
primary target of BOT-4-one is the IKK complex.
IKKb contains a cysteine residue at position 179 and serine
residues at 177 and 181 of the activation loop of the kinase
domain. Many reagents are known to inhibit IKKb kinase
activity by binding to cysteine-179, indicative of the impor-
tance of this residue for its biological activity (Gupta et al.,
2010; Jeon et al., 2003; Kim et al., 2007; Lee et al., 2006).
To investigate whether BOT-4-one targets cysteine or serine
residues in the activation loop of the IKKb kinase domain, we
measured SEAP expression and performed in vitro kinase
assays toward IKKb, followed by transfection with flag-tagged
wild-type or mutant IKKb plasmids. BOT-4-one effectively
inhibited SEAP expression and enzyme activity of wild-
type and SS/EE mutant IKKb transfection. However, SEAPwww.jidonline.org 109
Figure 2. BOT-4-one inhibits STAT activation. Mouse T cells (aee) and RAW264.7 cells (f) were pretreated with BOT-4-one for 1 hour before stimulation with
appropriate cytokines for 10e30 minutes. Western blot analysis was performed, and results are represented as one of the three independent experiments (n ¼ 3),
all of which showed similar results. AG, AG-490 (50 mM).
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110expression and catalytic activity of IKKb were not inhibited
by transfection with the C/A mutant IKKb (Figure 4b), indic-
ative of a direct interaction of BOT-4-one with cysteine-179
in the activation loop of IKKb.
Covalent docking of BOT-4-one at cysteine-179 of IKKb
To predict the covalent binding mode of BOT-4-one at
cysteine-179 of human IKKb, we performed a docking
experiment on the activation loop of IKKb with BOT-4-one
using a covalent docking module of Schro¨dinger suite 2014
(Schro¨dinger LLC, Cambridge, MA). Superimposition of the
apo-IKKb (PDB: 4E3C, green) and co-crystallized IKKb with
an inhibitor in the ATP pocket (PDB: 4KIK, red) revealed
that apo-IKKb is closed form and co-crystallized IKKb is
open form (see Supplementary Figure S5a, online). Covalent
binding of BOT-4-one with cysteine-179 of IKKb can allow for
1,2- or 1,4-nucleophilic addition (Supplementary Figure S5b),
and the molecular orbital package with PM3 semiempirical
molecular orbital methods implementing the Sybylx1.2
program (Tripos Inc., St. Louis, MO) revealed that 1,2-
nucleophilic addition is more favorable than the 1,4-
reaction (Supplementary Figure S5c). The binding energy of
the illustrated binding mode calculated using Prime MM-
GBSA module (Schro¨dinger LLC, Cambridge, MA) was DGbind
of 64.500 kcal/mol for apo-IKKb and e55.906 kcal/mol for
co-crystallized IKKb, indicating the apo-IKKb shows more
favorable binding with BOT-4-one (see Supplementary
Figure S6, online). BOT-4-one was well fitted into the activa-
tion loop of IKKb, converting from the carbonyl moietyJournal of Investigative Dermatology (2016), Volume 136of BOT-4-one to the hydroxyl group by 1, 2-nucleophilic
addition with cysteine-179. The covalently bound BOT-4-one
at cysteine 179 in the activation loop of IKKb showed two
hydrogen bonds with a threonine-180 backbone and tyrosine-
169 side chain, as well as hydrophobic interactions with
phenylalanine-26, arginine-47, and valine-183 (Figure 4c).
BOT-4-one alleviates hapten-induced allergic and atopic
dermatitis
Because BOT-4-one inhibits pathogenic CD4þ T-cell differ-
entiation and TCR-mediated signaling cascades, these
inhibitory activities suggest that BOT-4-one may have thera-
peutic effects toward inflammatory and autoimmune
disorders. To examine these pharmacologic activities using a
well-designed in vivo animal model, skin inflammation was
induced in mouse ears by epicutaneous challenge with
TNCB. TNCB application resulted in increased ear thickness
compared with the vehicle-treated group, indicating that
edematous ear swelling was induced by TNCB. Ear swelling
was effectively decreased by topical application of BOT-4-
one (Figure 5a). Histologic analysis revealed that TNCB
application markedly increased the signs of inflammatory
responses, including dense dermal infiltration of leukocytes,
epidermal hyperplasia, and hyperkeratosis in the mouse ears,
whereas BOT-4-one effectively reduced these inflammatory
responses (Figure 5b). Quantitative real-time PCR analysis
showed that the mRNA levels of Th1- and Th2-cell lineage-
specific cytokines, including IFN-g, IL-4, IL-5, and IL-13,
increased in the TNCB-challenged group, whereas mRNA
Figure 3. BOT-4-one inhibits TCR-mediated Akt and NF-kB signaling. (aec) Mouse T cells and RAW264.7 cells were pretreated with BOT-4-one for 1 hour
before stimulation with anti-CD3 and anti-CD28 antibodies (2 mg/ml) or either LPS (1 mg/ml) or zymosan (0.3 mg/ml) for 10e30 minutes. Western blot analysis
was performed with antibodies specific for the target molecules, and results are represented as one of the three independent experiments (n ¼ 3), all of which
showed similar results. GAPDH expression served as a loading control. PP2, Src family kinase inhibitor (100 nM); LY, LY294002 (50 mM); PD, PD98059 (40 mM);
SB, SB203580 (40 mM); SP, SP600125 (40 mM).
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Supplementary Figure S7a, online).
We further examined in vivo chronic allergic dermatitis by
repeated topical application of TNCB on the back of NC/Nga
mice that have been reported to develop atopic dermatitis
(AD)-like skin inflammation (Takahashi et al., 2005). The skin
of TNCB-challenged mice developed AD-like skin inflam-
mation showing increased hypertrophy, hyperkeratosis, and
dermal infiltration of leukocytes in the epidermis and dermis
compared with the vehicle-applied group. Regarding the
elevated AD-like inflammatory response, topical application
with BOT-4-one reduced these symptoms in the skin
(Figure 5c and d). To measure the number of infiltrating mast
cells in the skin lesions, we performed toluidine blue stain-
ing. In accordance with improvement of AD-like symptoms
in the skin of BOT-4-one-treated NC/Nga mice, this reagent
led to a reduction in mast cells compared with TNCB-
challenged mice, which was similar to the vehicle-applied
group (Figure 5d, blue). In addition, BOT-4-one significantly
reduced the amount of serum IgE and the production and
expression of Th1- and Th2-cell lineage-specific cytokines,including tumor necrosis factor-a, IFN-g, IL-4, IL-5, IL-12p70,
and IL-18 compared with the TNCB-challenged group
(Supplementary Figure S7b and c).
BOT-4-one ameliorates psoriasis-like skin inflammation
Together with allergic skin inflammatory models, we gener-
ated an autoimmune inflammatory disease model through
intradermal injection with IL-23 into the ears of mice to
induce psoriasis-like skin inflammation. Proinflammatory
cytokine IL-23 has been shown to induce inflammatory
autoimmune diseases such as psoriasis and rheumatoid
arthritis by activation of STAT3 signaling (Maddur et al.,
2012). IL-23 injection increased ear skin thickness
compared with the phosphate-buffered saline (PBS)-injected
group, indicative of edematous ear swelling, the first hall-
mark of local skin inflammation. Ear swelling decreased after
topical application of BOT-4-one (Figure 6a). Hematoxylin
and eosin-stained ear sections revealed markedly increased
skin thickness in the dermis and progression of inflammatory
skin damage such as hyperproliferative keratinocytes and
dermal infiltration of T lymphocytes, dendritic cells,www.jidonline.org 111
Figure 4. BOT-4-one targets cysteine-179 residue of the activation loop of IKKb kinase domain. (a) RAW264.7/NF-kB-SEAP-NPT cells were transfected with
expression vectors encoding TRAF-2, MyD88, MEKK-1, NIK-1, IKKb, NF-kB p50, or p65 subunit. After 24 hours, the cells were further incubated with vehicle
(0.1% DMSO) or BOT-4-one (30 mM) for 24 hours, and SEAP assay was performed. Data are presented as the means  standard deviation of three independent
experiments (n ¼ 3). **P < 0.005 versus LPS-stimulated or overexpression vector-transfected group. (b) RAW264.7/NF-kB-SEAP-NPT (top) or RAW264.7
(bottom) cells were transfected with flag-tagged IKKb expression vectors encoding wild-type, C/A, or SS/EE mutant. The cells were incubated for 24 hours in the
presence or absence of BOT-4-one (30 mM) and SEAP assay (top) and in vitro IKKb kinase assay (bottom) were performed. Data are presented as the means 
standard deviation of three independent experiments (n ¼ 3). **P < 0.005 versus overexpression vector-transfected group. (c) The predicted binding mode of
BOT-4-one. BOT-4-one covalently bound to cysteine-179 of the activation loop of IKKb kinase domain (PDB ID: 4E3C). The hydrogen bonding interactions of
BOT-4-one with residues of Thr-180 and Tyr-169 are shown as a green dotted line. The residues of Phe-26, Arg-47, and Val-183 having hydrophobic interactions
are represented as a stick model.
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112macrophages, and neutrophils in IL-23-injected mouse ears
compared with the PBS-injected group, whereas edematous
ear swelling and these pathologic inflammatory parameters
were effectively decreased by BOT-4-one (Figure 6b).
Quantitative real-time PCR showed that the mRNA levels of
well-known major inflammatory chemokines and Th17 cell
lineage-specific cytokines in psoriasis, including CXCL1,
CXCL10, CCL17, CCL20, CCL27, CCR4, CCR6, and IL-17A,
increased after IL-23 injection compared with the PBS-
injected group, and these mRNA levels were effectively
inhibited by BOT-4-one (Figure 6c). These in vivo data indi-
cate that BOT-4-one ameliorates skin inflammation and
autoimmune diseases involved in pathogenic Th1-, Th2-, and
Th17-cell subsets by regulating CD4þ T-cell differentiationJournal of Investigative Dermatology (2016), Volume 136and the complex network of cytokine-mediated signaling
cascades.
DISCUSSION
Benzoxathiole derivatives including 6-hydroxy-1,3-
benzoxathol-2-one and BOT-4-one have been reported
several biologically active properties (Goeth and Wildfeuer,
1969; Kim et al., 2008, 2011; Lius and Sennerfeldt, 1979;
Wildfeuer, 1970). Although the action mechanism of these
derivatives on NF-kB and JAK3/STAT3 signaling has been
recently defined, the molecular mechanisms underlying the
pharmacologic activities remain to be clarified. We specu-
lated that benzoxathiole derivatives could mediate some of
their pharmacologic activities by regulating TCR-mediated
Figure 5. BOT-4-one suppresses dermatitis-like skin inflammation in mice. (a and b) The abdomens of C57BL/6 mice were cutaneously sensitized by
application with vehicle (acetone:olive oil, 3:1) or 3% TNCB and challenged with 1% TNCB on the ears 6 days after sensitization. BOT-4-one (10 mg/kg) was
topically applied 1 hour before the TNCB challenge. Swelling (a) and hematoxylin and eosin staining (b) of the ears are shown. (c and d) The back of NC/Nga
mice was immunized by application with 1% TNCB and challenged with 0.2% TNCB three times per week for 5 weeks. BOT-4-one (10 mg/kg) was topically
applied once per day for 2 weeks. Macroscopic skin lesions (c) and histologic analysis (d) of the skin specimens are represented. #P < 0.005 versus vehicle-
treated group; **P < 0.005 versus TNCB-treated group (n ¼ 3).
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mation and autoimmune diseases. As a result, we demon-
strated that the benzoxathiole derivative BOT-4-one has
immunomodulatory activity. This activity was associated with
regulation of CD4þ T-cell differentiation, resulting in
amelioration of inflammatory and autoimmune skin diseases.
We further showed that BOT-4-one inhibited TCR-mediated
distal signaling cascades such as Akt and NF-kB signaling.
Generally, 6-hydroxy-1,3-benzoxathol-2-one, one of the
benzoxathiole derivatives, reported weak side effects such as
scalp and face dermatitis or contact dermatitis when used for
topical treatment of scalp psoriasis or patch test. In these
cases, 6-hydroxy-1,3-benzoxathol-2-one contained 0.2 to
1% or 40% concentration in the products. However, in our
cases, the maximum concentration of BOT-4-one is 30 mM
and 10 mg/kg for in vitro and in vivo experiments. The
concentrations were lower than 0.1%; therefore, we did not
observe any side effect.Complex networks of master transcription factors, STAT
proteins, and cytokines are responsible for the differentiation
of distinct CD4þ T-cell subsets. Although CD4þ T cells
regulate immune responses to pathogens by producing T-cell
lineage-specific cytokines, overproduction of these cytokines
is associated with the development of autoimmune and in-
flammatory diseases such as organ-specific autoimmunity,
induction and persistence of asthma and allergic diseases,
and autoimmune diseases (Akdis and Akdis, 2014; Fujinami
et al., 2006; Taams et al., 2006). Th1-specific signature
cytokines IFN-g and tumor necrosis factor-a activate mono-
nuclear phagocytes including macrophages, which is impli-
cated in organ-specific autoimmunity by infection of
intracellular pathogens such as bacteria and protozoa (Del
Prete, 1992; Guo et al., 2009). Th2 cells produce IL-4, IL-5,
IL-9, IL-10, IL-13, and IL-25, thereby acting as a hallmark for
the induction and persistence of asthma and allergic diseases
such as atopy (Del Prete, 1992; Guo et al., 2009). Th17 cellswww.jidonline.org 113
Figure 6. BOT-4-one suppresses psoriasis-like skin inflammation in mice. (a and b) Mouse ears were topically applied with either PBS or BOT-4-one (10 mg/kg)
1 hour before an intradermal injection with mouse IL-23 (500 ng/15 ml) into the ears of C57BL/6 mice every other day for 14 days. Swelling (a) and hematoxylin
and eosin staining (b) of the ears were performed. (c) Total RNAwas isolated and quantitative real-time PCR performed. #P < 0.005 versus vehicle-treated group;
**P < 0.005 versus IL-23-injected group (n ¼ 3).
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114are involved in the generation of autoimmune diseases by
producing IL-17, IL-21, IL-22, and IL-23, thereby controlling
extracellular bacterial and fungal infections (Harrington
et al., 2005). On the contrary, immunosuppressive cyto-
kines transforming growth factor-b and IL-10 are crucial for
the maintenance of immune cell homeostasis, which are
produced by Th2 and/or Treg subsets (Sakaguchi et al., 2009;
Yamane and Paul, 2012). BOT-4-one inhibited the mRNA
levels of T-bet, GATA-3, and RORgt, the master regulators of
Th1, Th2, and Th17 cell subsets, respectively, whereas those
of FoxP3, the master regulator of Treg cell subset, were
enhanced by BOT-4-one. Consistently, BOT-4-one effectively
inhibited the mRNA levels and production of CD4þ T-cell
lineage-specific inflammatory cytokine, whereas those of the
anti-inflammatory cytokine IL-10 were increased. These
observations suggested an immunomodulatory activity ofJournal of Investigative Dermatology (2016), Volume 136BOT-4-one through regulation of the balance of CD4þ T-cell
differentiation and production of their specific cytokines.
Skin inflammation and autoimmune diseases are induced
by various inflammatory cytokines produced by Th1-, Th2-
and/or Th17-cell subsets with complex networks of signaling
cascades (Bieber, 2008; Dornmair et al., 2003; Johnson-
Huang et al., 2012). To determine the therapeutic potential
of BOT-4-one in these diseases, in vivo experiments were
performed due to the immunomodulatory activity of BOT-4-
one through regulation of CD4þ T cell differentiation into
distinct Th-cell subsets. Skin inflammation and autoimmune
diseases were induced by topical application of TNCB to the
skin of mice or intradermal injection with IL-23 into the ears
of mice, which are known to induce allergic contact
dermatitis, AD-like skin inflammation, and psoriasis-like
chronic skin inflammation (Kim et al., 2013b, 2014;
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progression of allergic and autoimmune inflammatory dis-
eases in the skin mediated from inappropriately activated
CD4þ T-cell subsets.
Regarding the molecular mechanisms of BOT-4-one
showing the immunomodulatory activity, we observed that
BOT-4-one inhibited several types of cytokine-induced acti-
vation of the STAT proteins, including STAT1, STAT3, STAT4,
STAT5, and STAT6, which are important transcription factors
during CD4þ T-cell differentiation (O’Shea et al., 2011).
Activated STAT proteins are generally found in diseases
showing inflammation, autoimmunity, and cancer, which
highlight the importance of these proteins in the development
of therapeutic targets for these diseases. TCR signaling cas-
cades are activated by presentation of the antigen peptide
derived from foreign antigen. This event activates proximal
signaling Src family tyrosine kinases Lck and Fyn and sub-
sequently leads to the activation of multiple distal signaling
pathways (Brownlie and Zamoyska, 2013; Huse, 2009). BOT-
4-one effectively inhibited TCR-mediated distal signaling
phosphatidylinositol 3-kinase/Akt and NF-kB signaling but
had a weak to no effect on proximal Src family kinase
signaling.
In conclusion, we observed that the benzoxathiole BOT-4-
one has immunomodulatory activity that regulates immune
responses and suppresses inflammatory and autoimmune
diseases in the skin of mice. These activities are associated
with regulation of CD4þ T-cell differentiation and TCR-
mediated distal signaling cascades. Our study demonstrated
that BOT-4-one has immunomodulatory activity, resulting in
amelioration of inflammatory and autoimmune skin diseases
through suppression of pathogenic CD4þ T-cell differentia-
tion and the overall immune response. Our data suggest that
BOT-4-one is a promising candidate molecule for the treat-
ment of inflammatory and autoimmune diseases mediated by
pathogenic CD4þ T-cell subsets.
MATERIALS AND METHODS
In vitro differentiation of mouse CD4D T cells
Naı¨ve CD4þ T cells isolated from the spleens of C57BL/6 mice were
enriched using a mouse CD4þ T-cell enrichment column (R&D
Systems, Minneapolis, MN) and purified by negative selection using
the MACS column (Miltenyi Biotech, San Diego, CA). Cells were
incubated for 5 days with mouse anti-CD3 and anti-CD28 antibodies
(2 mg/ml). To differentiate into specific lineages of T-cell subsets, the
cells were polarized under Th1, Th2, Th17, or Treg polarizing con-
ditions, as described previously (Kim et al., 2013b, 2014).
Cell culture
RAW264.7 cells were maintained in DMEM containing 10% fetal
bovine serum, 2 mM L-glutamine, and 1% penicillin/streptomycin
solution. RAW264.7 cells expressing pNF-kB-SEAP-NPT reporter
construct (RAW264.7/NF-kB-SEAP-NPT) were maintained in the
same media for RAW264.7 cells, except they were supplemented
with 500 mg/ml G418, as described previously (Moon et al., 2001).
SEAP reporter assay
SEAP reporter activity was measured using the supernatants of
cultured RAW264.7/NF-kB-SEAP-NPT cells, as described previously
(Kim et al., 2008, 2013a). Detailed experimental protocols are
provided in the Supplementary Materials (see online).In vitro IKKb kinase assay
The IKKb enzyme was prepared by immunoprecipitation with anti-
flag affinity gel freezer-safe beads (Sigma-Aldrich, St. Louis, MO)
on ice for 2 hours from whole cell lysates of the RAW264.7 cells
transfected with flag-tagged IKKb expression vectors encoding wild-
type, C/A (cysteine-to-alanine substitution at position 179), or SS/EE
(serine-to-glutamic acid substitutions at positions 177 and 181)
mutant. The IKKb kinase assay was performed by incubation with the
beads, 5 mCi [g-32P]ATP (PerkinElmer NEN Radiochemicals, Wal-
tham, MA), and GST-IkBa (2 mg; Santa Cruz Biotechnology, Dallas,
TX) in assay buffer at 30 C for 1 hour, and the radioactive bands
were visualized with x-ray film, as described previously (Kim et al.,
2008, 2013c).
Molecular modeling
The x-ray diffraction structure of human IKKb (PDB ID: 4E3C) (Polley
et al., 2013) was used for covalent docking with BOT-4-one. The
protein structure and ligand were prepared under the standard
procedure of the Protein Preparation Wizard and Ligprep modules in
Maestro v9.5 (Schro¨dinger LLC, Cambridge, MA). The mutated
glutamate residues in the crystal structure of 4E3C at positions 177
and 181 in the activation loop of the kinase domain were replaced
by serine residues of the original sequence of human IKKb for
docking studies. The binding mode of BOT-4-one on IKKb was
predicted using covalent docking module in Maestro v9.5. The re-
action type with reactive atoms was set to nucleophilic addition with
cysteine-179 of IKKb. The grid box was automatically determined as
residues within 5.0 A˚ of the cysteine-179. After minimization of
residues within 3 A˚ of the covalently bound ligand, the output of 10
poses of ligand-receptor complexes was scored using Prime MM-
GBSA to calculate binding energy.
Allergic contact dermatitis
All animal experiments were reviewed according to the “Guide for
Animal Experiments” by the Institutional Animal Care and Use
Committee at Seoul National University. The experimental protocols
were approved by the committee on the Ethics of Animal Experi-
ments of Seoul National University. The abdomens of C57BL/6 mice
were shaved and sensitized cutaneously with 3% TNCB (100 ml; TCI,
Japan). Six days after sensitization, the mice were challenged with
1% TNCB (15 ml) on both sides of the ears, followed by topical
application of vehicle (1% DMSO) or BOT-4-one (10 mg/kg).
AD model
The back of NC/Nga mice was shaved and immunized by cutaneous
application of 1% TNCB (200 ml). Four days after immunization, AD
was induced by topical application with 0.2% TNCB (150 ml) on the
back of mice three times per week for 5 weeks. The mice were
topically applied with vehicle (1% DMSO) or BOT-4-one (10 mg/kg)
once per day for 2 weeks after the model was established.
Psoriasis-like skin inflammation
Recombinant mouse IL-23 (500 ng/15 ml; eBioscience) was intra-
dermally injected into the ears of C57BL/6 mice, as reported pre-
viously (Kim et al., 2013b, 2014), followed by topical application of
vehicle (1% DMSO) or BOT-4-one (10 mg/kg) every other day for
14 days.
Histologic analysis
Tissues were fixed with 4% paraformaldehyde in PBS for 24 hours,
washed with tap water, dehydrated with grade ethanol, and then
embedded in paraffin. The paraffin blocks were cut in 4-mm thick
sections, mounted on glass slides, dewaxed, rehydrated with gradewww.jidonline.org 115
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116ethanol, and then stained with hematoxylin and eosin. Analysis was
performed using a microscope (Olympus, Japan).
Statistics
Results were represented as means  standard deviation of three
independent experiments. Statistical differences were determined
using one-way analysis of variance followed by Dunnett’s multiple
comparison tests. Differences were considered statistically signifi-
cant at P < 0.05.
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